Glucotrack and Lōkahi Therapeutics complete reverse merger
Glucotrack (Nasdaq: GCTK) has completed a business combination with Lōkahi Therapeutics, giving the private biopharmaceutical company control of a listed vehicle and creating what both parties describe as a capital-efficient platform for acquiring and advancing differentiated healthcare assets.
Under the deal structure, Lōkahi securityholders received a mix of Glucotrack common stock and convertible preferred stock. Once the preferred shares convert, subject to stockholder approval and Nasdaq listing requirements, Lōkahi holders are expected to own approximately 90% of the combined company on a fully diluted basis. E.F. Hutton & Co. acted as exclusive financial adviser on the transaction.
Erik Emerson has been appointed chief executive of the combined entity. Paul Goode, formerly leading Glucotrack, assumes the role of chief technical officer at the group level and chief executive of the continuing glucose-monitoring subsidiary.
The deal
The transaction effectively preserves Glucotrack's continuous blood glucose monitoring (CBGM) technology inside a ring-fenced wholly owned subsidiary, with a portion of a planned private placement earmarked to fund its continued development. The CBGM device remains an investigational product and has not yet received FDA clearance.
Lōkahi's operating model centres on what it calls its "ai²" platform, a framework the company says integrates AI-assisted asset identification with cross-functional development expertise. The company describes the combination as a "dual-engine" structure: one engine being the late-stage clinical programme it came in with, the other being the AI-driven sourcing capability. Neither the indication for the late-stage programme nor specific pipeline assets were identified in the announcement.
Emerson said the deal positions the combined company to "expand our pipeline, strengthen our capital structure, and pursue a broader set of strategic opportunities." The statement carries the shape of a platform-company thesis rather than a single-asset story.
Market context
The reverse-merger route into a public listing has become a recurring structure for smaller biotech and biopharma companies seeking capital market access without the cost and timeline of a conventional IPO. Nasdaq-listed shells left by companies that pivoted or ran out of capital have attracted acquirers in diagnostics, digital health and rare disease over the past two years. Regulatory scrutiny of these transactions has tightened, with the SEC and Nasdaq increasing their due-diligence requirements around shell quality, shareholder dilution and disclosure.
Lōkahi's positioning as a "platform" that acquires overlooked assets using AI-assisted screening places it in a crowded field. A number of publicly listed and private operators have adopted similar models in recent years, arguing that AI-driven target identification can surface undervalued programmes that larger organisations have deprioritised. Whether that thesis translates into clinical or commercial value typically takes several years to test, and investors will look for concrete pipeline disclosures in the near term to gauge the platform's substance beyond its structure.
The CBGM technology, now operating as a subsidiary, will compete in a continuous glucose monitoring market dominated by established device companies with large installed bases, where regulatory clearance timelines and reimbursement coverage remain the primary barriers for new entrants.